RxSight (RXST) Stock Price, News & Analysis

Company Overview

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Key Stats

• Today's Range: $14.59 to $15.03
• 50-Day Range: $14.08 to $29.29
• 52-Week Range: $13.50 to $66.54
• Volume: 33,190 shs
• Average Volume: 639,393 shs
• Market Capitalization: $607.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.60
• Consensus Rating: Hold

RxSight Stock Analysis - MarketRank™

RxSight scored higher than 53% of companies evaluated by MarketBeat, and ranked 393rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

RxSight has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 4 buy ratings, 4 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

RxSight has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for RxSight are expected to grow in the coming year, from ($0.70) to ($0.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of RxSight is -17.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RxSight is -17.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

RxSight has a P/B Ratio of 3.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.51% of the float of RxSight has been sold short.

Short Interest Ratio / Days to Cover

RxSight has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in RxSight has recently increased by 16.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RxSight does not currently pay a dividend.

Dividend Growth

RxSight does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.51% of the float of RxSight has been sold short.

Short Interest Ratio / Days to Cover

RxSight has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in RxSight has recently increased by 16.19%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.91

News Sentiment

RxSight has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for RxSight this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for RXST on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, RxSight insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $179,970.00 in company stock.

Percentage Held by Insiders

Only 9.36% of the stock of RxSight is held by insiders.

Percentage Held by Institutions

78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RXST Stock Analysis - Frequently Asked Questions

How have RXST shares performed this year?

RxSight's stock was trading at $34.38 at the start of the year. Since then, RXST shares have decreased by 57.2% and is now trading at $14.72.
View the best growth stocks for 2025 here.

How were RxSight's earnings last quarter?

RxSight, Inc. (NASDAQ:RXST) posted its quarterly earnings results on Tuesday, February, 25th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by $0.25. The company earned $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative net margin of 23.92% and a negative trailing twelve-month return on equity of 14.00%.
Read the conference call transcript.

When did RxSight IPO?

RxSight (RXST) raised $125 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share.

Who are RxSight's major shareholders?

Top institutional shareholders of RxSight include Bank of New York Mellon Corp (0.26%), Sara Bay Financial (0.24%), Rhumbline Advisers (0.13%) and Paragon Advisors LLC (0.12%). Insiders that own company stock include Ronald M Md Kurtz, Eric Weinberg, Ilya Goldshleger, Ilya Goldshleger, Julie Andrews, Bakker Juliet Tammenoms, Robert Keith Warner, Tamara Fountain, William J Phd Link, Shelley B Thunen, Shweta Maniar and Jesse Anderson Corley.
View institutional ownership trends.

How do I buy shares of RxSight?

Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of RxSight own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RxSight investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), ServiceNow (NOW), Arista Networks (ANET) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 2/25/2025
• Today: 5/01/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Ophthalmic goods
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:RXST
• CIK: 1111485
• Web: www.rxsight.com
• Phone: 949-521-7830
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $37.60
• High Stock Price Target: $73.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +155.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-48,610,000.00
• Net Margins: -23.92%
• Pretax Margin: -23.91%
• Return on Equity: -14.00%
• Return on Assets: -12.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.67
• Quick Ratio: 11.71

Sales & Book Value

• Annual Sales: $139.93 million
• Price / Sales: 4.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.47 per share
• Price / Book: 3.29

Miscellaneous

• Outstanding Shares: 40,620,000
• Free Float: 36,532,000
• Market Cap: $597.93 million
• Optionable: Optionable
• Beta: 1.26